All News

The Nerivio REM device demonstrated a statistically significant reduction in migraine days/month vs a placebo device in both chronic and episodic migraine.

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.

Your daily dose of clinical news you may have missed.

An OTC progestin only pill could potentially reduce the number of annual unintended pregnancies in the US by tens of thousands, a novel modeling study reveals.

AHA 2022: Chronic users of either e-cigarettes or traditional cigarettes had acute changes in cardiovascular function and performed worse on exercise stress testing than never users in new study.

Apixaban was associated with up to a 28% lower risk of GI bleeding vs the 3 other direct oral anticoagulants in the first large-scale comparative analysis.

RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.

Your daily dose of clinical news you may have missed.

The American Gastroenterological Association released its first medical guideline recommending prescription medications for weight loss in adults with obesity. A review, here.

ObesityWeek® 2022. Primary care clinicians report providing on average just 70% of a wide range of clinical weight management services, according to a new survey.

Your daily dose of clinical news you may have missed.

AHA 2022: An estimated 18% of Americans with heart disease reported using wearables, compared with 29% of the total US population.

The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.

Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.

ObesityWeek 2022: Regardless of the number of obesity-related comorbidities, tirzepatide was associated with a greater reduction in body weight than placebo.

Use of telemedicine and home blood pressure monitoring may mitigate adverse impact on BP control during future large-scale emergencies, noted researchers.

Your daily dose of clinical news you may have missed.